Thomas Parr, PhD

Thomas Parr, PhD

Tom Parr, PhD, has more than 26 years drug discovery experience across both large pharmaceutical and small biotechnology companies. Prior to joining Spero, Dr. Parr was the Chief Scientific Officer at Fedora Pharmaceuticals where the company moved novel diazabicyclooctane beta-lacramase inhibitors toward development partnerships. Prior to Fedora he was the Chief Scientific Officer at Targanta Therapeutics, now part of The Medicines Company. While at Targanta, Dr. Parr was instrumental in progressing the lipoglycopeptide, oritavancin through Phase 3 trials to registration with the FDA. Dr. Parr has worked on a broad range of marketed antibiotics including beta-lactams (cefaclor, loracarbef, cefuroxime axetil, cephalexin, moxalactam, ceftazidime, cefazolin, RWJ-333441); glycopeptides (vancomycin and oritavancin); lipodepsipeptides (daptomycin); aminoglycosides (tobramycin); quinolones (cinoxacin); macrolides (dirythromycin); antimicrobial peptides (iseganins); and a variety of additional developmental candidates.

Dr. Parr earned his PhD from the University of Calgary and conducted a postdoctoral fellowship at the University of British Columbia. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development career.